New drug combo aims to tame advanced cancers in early trial
NCT ID NCT04443088
First seen Mar 21, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tests an experimental drug called INV-1120, given alone or with pembrolizumab (a standard immunotherapy), in adults with advanced solid tumors that have stopped responding to other treatments. The main goals are to find safe doses and identify side effects. About 78 participants will take part in this early-phase, open-label trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Horizon Oncology Research, LLC,
COMPLETEDLafayette, Indiana, 47905, United States
-
START
COMPLETEDSan Antonio, Texas, 78229, United States
-
UT Health
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.